1 terminated, 1 withdrawn. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 1, Withdrawn 1 |
Follow Folotyn: new trials by email Literature Review of Folotyn trials Research Report on Folotyn
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL Romidepsin, Pralatrexate - Lymphoma, T-Cell, Peripheral | Phase 3 | Withdrawn | Jennifer Amengual | 2018-09-01 | 2018-12-19 | |
| Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients Pralatrexate Injection - Peripheral T-cell Lymphoma | Phase 3 | Terminated | Spectrum Pharmaceuticals, Inc | 21 | 2011-08-01 | 2021-11-19 |
Lymphoma, T-Cell, Peripheral (2) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1) · Lymphoproliferative Disorders (1)
Jennifer Amengual (1) · Spectrum Pharmaceuticals, Inc (1)
Australia (1) · Belgium (1) · Canada (1) · France (1) · Ireland (1) · Israel (1) · Italy (1) · New Zealand (1) · Poland (1) · Puerto Rico (1) · Spain (1) · United Kingdom (1) · United States (1)